TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06921837: A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer

Sponsor: Bolt Biotherapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 122 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,521,590

Rescue Site Savings

+$5,615,610

Unlock Full NCT06921837 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06921837 Rescue Dossier →